TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20057344
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVTA) injection plus panretinal photocoagulation (PRP) and macular photocoagulation (MPC)
Study: 16123680
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alpha‐2b 1.5 microg/kg/wk and ribavirin 800‐1200 mg/d for 24 weeks
Study: 12469988
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg and 10 mg once daily)
Study: 7579555
Drug: Tropisetron, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron, 5 mg o.d. plus dexamethasone, 12 mg i.v. on day 1 followed by 4 mg orally b.i.d. on days 2‐5
Study: 7579555
Drug: Tropisetron, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron, 5 mg o.d.
Study: 6106611
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 250 mg
Study: 6106611
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 500 mg
Study: 27321790
Drug: Levosimendan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (10 µg/kg bolus followed by infusion at a rate of 0.1 µg/kg/min for 24 hours)
Study: 27321790
Drug: Milrinone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50 µg/kg bolus followed by infusion at a rate of 0.5 µg/kg/min for 24 hours)
Study: 11977638
Drug: Amifostin (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostin (treatment group A)
Study: 7268356
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sulfinpyrazone with sodium load
Study: 30635007
Drug: TEAS combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEAS combined with opioid drugs
Study: 30461602
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol anesthesia
Study: 27884128
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic treatment (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 at a dose of 7 × 10^9 colony-forming units one per day until birth)
Study: 19681775
Drug: Glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.5 g/kg/day)
Study: 18835506
Drug: Isonitrogenous, isocaloric,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonitrogenous, isocaloric, isovolemic nutritional solution
Study: 12034156
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg TID in addition to diuretics, digoxin, enalapril and carvedilol
Study: 12034156
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diuretics, digoxin, enalapril and carvedilol)
Study: 9562007
Drug: Alteplase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (100 mg 2-h infusion)
Study: 3204147
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg administered 12 h before hCG injection and 48 h before oocyte capture
Study: 329406
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU of calciferol daily for 8 months
Study: 29752009
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (2 g daily, 8 weeks)
Study: 25137844
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (sufentanil combined propofol)
Study: 25137844
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with intravenous anesthesia (sufentanil, propofol combined with acupuncture)
Study: 19067708
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% and Vehicle (control)
Study: 16027437
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with alpha‐tocopherol (400 IU/d) and beta‐carotene (30 mg/d)
Study: 12004847
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5‐FU (600 mg/m2 24‐hour infusion for five days, then 600 mg/m2 IV once a week) and IFN (5 MU subcutaneously three times a week for six months)
Study: 12004847
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leucovorin (20 mg/m2 rapid intravenous injection) and 5‐FU (425 mg/m2 IV days 1‐5 every 28 days for six cycles)
Study: 10457120
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg u.i.d.) plus flunisolide (two 25 microg puffs per nostril morning and night)
Study: 28249612
Drug: Cisplatin chemo‐irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin chemo‐irradiation with SIB-IMRT, escalating total dose to the GTV up to 80.5 Gy. Chemotherapy planned either in the 1st and 5th week (cisplatin 20 mg/m2/d d 1-5 and d 29-33) or weekly (cisplatin 40 mg/m2/d) during RT. RT delivered as SIB with total doses of 80.5 Gy/70.0 Gy/56.0 Gy with 2.3 Gy/2.0 Gy and 1.6 Gy.
Study: 28249612
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm with cisplatin chemo‐irradiation, total doses of 70.0 Gy/56.0 Gy with 2.0 Gy and 1.6 Gy.
Study: 28249612
Drug: Pre-study with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-study with dose escalation up to 77.0 Gy/70.0 Gy/56.0 Gy with 2.2 Gy/2.0 Gy and 1.6 Gy.
Study: 24176010
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg R. crenulata extract
Study: 17309996
Drug: Cross-linked hyaluronic
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-linked hyaluronic acid injections
Study: 17309996
Drug: Vehicle (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (isotonic sodium chloride) injections
Study: 15115710
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg every 3 days for 3 injections)
Study: 9862512
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) alone, 18 x 10(6) IU/m2, 24-hour i.v. infusion cycles, days 1 to 4, for 25 weeks
Study: 9862512
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) alone, 6 x 10(6) IU/m2, days 1, 3, and 5, weekly for 52 weeks
Study: 9862512
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFN and IL-2, same doses as above, for 24 weeks
Study: 8541104
Drug: Monoclonal Lewis
Normalized name: sialyl Lewis A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal Lewis Y antibody (100 mg, six doses over 2 weeks)
Study: 8541104
Drug: Placebo regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo regimen (six infusions of human serum albumin)
Study: 22850121
Drug: Rifapentine 10
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 10 mg/kg/dose, administered 5 days per week for 8 weeks
Study: 22850121
Drug: Rifampin 10
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks
Study: 19232887
Drug: Polished surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polished surface treatment
Study: 19232887
Drug: Matte surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matte surface treatment
Study: 19232887
Drug: Polymethyl methacrylate‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymethyl methacrylate‐coated surface treatment
Study: 16300701
Drug: Injection triamcinolone
Normalized name: triamcinolone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection triamcinolone acetonide with lignocaine
Study: 16300701
Drug: Injection lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection lignocaine alone
Study: 8542460
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered sodium cromoglycate
Study: 2611040
Drug: Immunotherapy (corynebacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (corynebacterium parvum s.c. around the scar 2 weeks after mastectomy) in node negative patients
Study: 2611040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immunotherapy and CMF in node positive patients
Study: 2611040
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further adjuvant therapy in node positive patients
Study: 2611040
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further adjuvant therapy in node negative patients
Study: 611325
Drug: Validation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validation group (30 subjects) administered the Astrand‐Rhyming Test using the established multiple regression equation to predict workload.
Study: 18808335
Drug: DNA priming
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA priming vaccine
Study: 18808335
Drug: MVA boosting
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA boosting vaccine
Study: 18808335
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of HIV‐1 DNA administered intradermally
Study: 15770115
Drug: Sertraline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (150 mg/day)
Study: 15367045
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (225 mg/day)
Study: 17196045
Drug: Sertraline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (150 mg/day) at maximum dose for 3 weeks
Study: 17196045
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (225 mg/day) at maximum dose for 3 weeks
Study: 12689612
Drug: Fenfluramine administration
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine administration
Study: 2440159
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml Pentastarch
Study: 2440159
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml Pentastarch
Study: 2440159
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml Pentastarch
Study: 2104531
Drug: Silicone cream
Normalized name: REMEDY SILICONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone cream with 20% silicone oil and occlusive dressing technique
Study: 2104531
Drug: Simple application
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple application of silicone cream
Study: 6997360
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of anesthetic
Study: 31030100
Drug: THD monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THD monotherapy
Study: 16945121
Drug: Silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4 mg twice daily
Study: 19531419
Drug: 2-g amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g amoxicillin tablets 1 hour before surgery
Study: 11141929
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic therapy (Control)
Study: 7828613
Drug: SPET using
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPET using technetium‐99m d,l‐hexamethylpropylene amine oxime (99mTc‐HMPAO)
Study: 31656059
Drug: FENO-guided algorithm
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO-guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long-acting beta-agonist (LABA) added for uncontrolled symptoms)
Study: 26136594
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D and plasma insulin concentrations
Study: 20929998
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with nuts (30 g/day)
Study: 17678911
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant FSH (75-150 IU/d) + GnRH antagonist (0.25 mg/d)
Study: 16573259
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% cream plus clindamycin 1%/benzoyl peroxide 5% gel
Study: 14574651
Drug: Severe smoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe smoke inhalation cases
Study: 6382224
Drug: nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20 mg twice a day
Study: 6382224
Drug: mefruside 25
Normalized name: mefruside 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefruside 25 mg once a day
Study: 31829187
Drug: Organic rumen‐protected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic rumen‐protected fat (RPF) supplement (0.45 kg/d)
Study: 25556460
Drug: Nimotuzumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab combined with DCF chemotherapy
Study: 25556460
Drug: Standard DCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DCF chemotherapy
Study: 15951292
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential (HDS) chemotherapy plus high-dose mitoxantrone and melphalan with autologous stem-cell transplantation (ASCT)
Study: 15951292
Drug: Outpatient dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient dose-dense chemotherapy regimen (MegaCEOP)
Study: 15951292
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential (HDS) chemotherapy plus ASCT
Study: 7659407
Drug: 0.60% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.60% NaCl solution
Study: 7659407
Drug: 0.45% NaCl
Normalized name: LVP solution Dextrose 5% with 0.45% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% NaCl solution
Study: 21210833
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser treatment
Study: 16167748
Drug: Early feeding
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early feeding group (sips of water within 6-8 hours, followed by oral soup or milk at least 150 millilitres at a time within 8-12 hours post-operative)
Study: 16167748
Drug: Routine feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine feeding group (restricted oral intake for 24 hours, administration of oral sips of water 24-48 hours post-operative)
Study: 1347222
Drug: Nondepolarizing regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondepolarizing regimen with doses ranging from approximately 1.5 to 6 times the ED95, with or without a priming dose
Study: 2939008
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of probucol and colestipol (treatment group)
Study: 30340627
Drug: Standard attentional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard attentional bias task (non-treatment)
Study: 20116631
Drug: Virosome vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome vaccine (n=43)
Study: 20116631
Drug: Split vaccine
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split vaccine (n=47)
Study: 18590393
Drug: Preoperative nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative nerve block (NB) with 0.25% 5‐8 ml bupivacaine mixed with 20‐40 mg methylprednisolone
Study: 12468165
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Study: 7671159
Drug: Sodium ethiodronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ethiodronate 400 mg p.o., 15 days every 3 months (n = 23)
Study: 2248063
Drug: Moclobemide (reversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (reversible inhibitor of monoamine oxidase-A)
Study: 29718385
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 (10 mg)
Study: 29718385
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 (25 mg)
Study: 29718385
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 (50 mg)
Study: 29718385
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 (100 mg)
Study: 8471409
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vanoxerine after fasting
Study: 8471409
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vanoxerine after low-fat meal
Study: 3803702
Drug: Esaprazole 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaprazole 600 mg
Study: 20819587
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (r-Sak or rt-PA)
Study: 20819587
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with rescue PCI
Study: 8894721
Drug: Trapezius microcurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapezius microcurrent therapy
Study: 1815069
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 100 mg sulpiride
Study: 1815069
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 100 mg sulpiride
Study: 6404341
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisolone (33 patients)
Study: 6404341
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisolone (34 patients)
Study: 30505604
Drug: Metoprolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.1 mg kg‐1) and tramadol (1 mg kg‐1)
Study: 30505604
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 μg kg‐1 bolus followed by 0.25‐0.5 μg kg‐1 min‐1 infusion)
Study: 23834392
Drug: Combined inhalation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inhalation of beta2-agonists (salbutamol, formoterol, salmeterol)
Study: 19464026
Drug: Pramlintide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (both doses)
Study: 11801508
Drug: Unoprostone twice
Normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unoprostone twice daily
Study: 9695964
Drug: Interferon alpha,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha, 3 x 10(6) units/m2 subcutaneously three times weekly until relapse
Study: 7986464
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily (n = 77)
Study: 7986464
Drug: Nicardipine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 50 mg twice daily (n = 77)
Study: 16396765
Drug: High-dose mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mitoxantrone combined with once daily cytarabine
Study: 14700448
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) strategies, including maximally tolerated doses, switching medications, combining dissimilar medications, and combining psychotherapy with medication.
Study: 14700448
Drug: Monotherapy (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (current first-line standard of care)
Study: 12374491
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 300 mg/d
Study: 12374491
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 600 mg/d
Study: 12374491
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 1200 mg/d
Study: 9879213
Drug: Conventional (panoramic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (panoramic + intra-oral radiographs)
Study: 8026236
Drug: 90-ml oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-ml oral sodium phosphate preparation
Study: 8026236
Drug: 4-liter polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-liter polyethylene glycol solution
Study: 8026236
Drug: sulfate-free 4-liter
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfate-free 4-liter polyethylene glycol solution